| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8101743 | ASTRAZENECA AB | Modulation of transthyretin expression |
Apr, 2025
(10 months from now) | |
| US9127276 | ASTRAZENECA AB | Conjugated antisense compounds and their use |
May, 2034
(9 years from now) | |
| US9181549 | ASTRAZENECA AB | Conjugated antisense compounds and their use |
May, 2034
(9 years from now) | |
| US10683499 | ASTRAZENECA AB | Compositions and methods for modulating TTR expression |
Aug, 2034
(10 years from now) | |
Wainua (Autoinjector) is owned by Astrazeneca Ab.
Wainua (Autoinjector) contains Eplontersen Sodium.
Wainua (Autoinjector) has a total of 4 drug patents out of which 0 drug patents have expired.
Wainua (Autoinjector) was authorised for market use on 21 December, 2023.
Wainua (Autoinjector) is available in solution;subcutaneous dosage forms.
Wainua (Autoinjector) can be used as treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis.
Drug patent challenges can be filed against Wainua (Autoinjector) from 22 December, 2027.
The generics of Wainua (Autoinjector) are possible to be released after 25 August, 2034.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-461) | Dec 21, 2030 |
| New Chemical Entity Exclusivity(NCE) | Dec 21, 2028 |
Drugs and Companies using EPLONTERSEN SODIUM ingredient
NCE-1 date: 22 December, 2027
Market Authorisation Date: 21 December, 2023
Treatment: Treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis
Dosage: SOLUTION;SUBCUTANEOUS
WAINUA (AUTOINJECTOR) family patents
